Mazdutide official-source update · version 1
This page preserves this version’s findings and source pins. Open the current profile →
Official-source update
Reviewed 2026-09-19 · Preserved version 1
Two phase 2 records concern different programs
NCT04904913 describes a 328-participant Chinese study of IBI362 with a 24-week weight endpoint. NCT06124807 describes a separate 179-participant LY3305677 study with a 32-week primary endpoint and 48-week follow-up. Their results are not interchangeable. NCT04904913 ↗NCT06124807 ↗
More findings and the sources behind them
Selected sponsor-submitted ClinicalTrials.gov records retrieved September 19, 2026, with design, population, endpoint and result-availability checks. This does not complete a registry search or replace primary-publication appraisal.
The later record includes posted weight results
The LY3305677 registry reports modeled mean weight changes of −7.33%, −15.6% and −18.1% across the three active groups versus −0.85% for placebo at week 32. These are changes from baseline in that study, not placebo-adjusted percentages or a cross-drug ranking. NCT06124807 ↗
Longer follow-up involved attrition
The same registry lists 179 participants starting and 128 completing the study. Its repeated-measures estimates should not be mistaken for measurements observed in every participant at every visit; adverse events were among several discontinuation reasons. NCT06124807 ↗
Result availability differs between the two records
The retrieved Chinese phase 2 record has no posted summary-results section, while the LY3305677 record does. Neither registry entry alone establishes the current authorization status in any jurisdiction. NCT04904913 ↗NCT06124807 ↗
What remains to be checked
- Reconcile Chinese and international trial families and current jurisdiction-specific regulatory documents.
- Appraise original publications and analysis plans, including missing-data assumptions and safety outcomes.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects ↗
Source dated 2025-11-17; retrieved 2026-09-19.
- protocolSection.identificationModule, designModule and armsInterventionsModule
- protocolSection.outcomesModule
- protocolSection.statusModule; presence or absence of resultsSection in retrieved record
SHA-256:
17c6c04046246d485b210ec2cb9946d088d8900d75328bba03e1f36b8da05d53A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight ↗
Source dated 2026-04-21; retrieved 2026-09-19.
- protocolSection.identificationModule, designModule and armsInterventionsModule
- resultsSection.participantFlowModule
- protocolSection.outcomesModule
- resultsSection.outcomeMeasuresModule
- protocolSection.statusModule; presence or absence of resultsSection in retrieved record
SHA-256:
d0ae75ea6041b13d872f7113133b4e3280c8ef42504e8b51bab39c9fabea9d30